Sara Onali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sara Onali has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Livia Biancone
From the Cattedra di Gastroenterologia e
21 shared publications - Emma Calabrese
Gastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
20 shared publications - Francesco Pallone
Department of Internal Medicine, Gastrointestinal Unit, Tor Vergata University of Rome, Rome, Italy
19 shared publications Francesca Zorzi
18 shared publicationsCarmelina Petruzziello
15 shared publicationsGiovanna Condino
13 shared publications
Latest Publications
- Open Access
- 22 July 2020
- Published by MDPI AG in Biomedicines
- Vol. 8 (8) , 234
A Novel Smad7 Genetic Variant Mapping on the Genomic Region Targeted by Mongersen Is Associated with Crohn’s Disease
Background: Down-regulation of Smad7 with a specific Smad7 antisense (AS) oligonucleotide-containing oral drug (Mongersen) was effective in pre-clinical studies and initial clinical trials in Crohn’s disease (CD) patients. A recent phase 3 trial was discontinued due to an apparent inefficacy of the drug, but factors contributing to the failure of this study remain unknown. Here, we analysed the frequency in CD of rs144204026 C/T single nucleotide polymorphism (SNP), which maps on the corresponding region targeted by the Smad7 AS contained in the Mongersen formulation and examined whether such a variant allele affects the ability of Smad7 AS to knockdown Smad7. Methods: rs144204026 SNP frequency was evaluated in two independent Italian cohorts of Crohn’s disease patients and normal controls. Genotyping was performed by allelic discrimination assay. Smad7 expression was evaluated in wild-type or heterozygous PBMCs treated with Smad7 AS. Results: No TT genotype was seen in CD patients and controls. Heterozygous genotype was more frequent in CD patients of both cohort 1 (11/235, 4.68%) and cohort 2 (8/122, 6.56%) as compared to controls (6/363, 1.65%; p = 0.029 and p = 0.01 respectively). Overall, a statistically significant association was observed between the T variant allele and CD patients’ susceptibility (p = 0.008; OR = 3.28, 95%CI: 1.3–8.3). Smad7 AS down-regulated Smad7 RNA independently of the presence of the variant allele. Conclusions: This is the first study to show an association between Smad7 rs144204026 SNP and CD patients. Data indicate that such a variant does not negatively influence the in vitro inhibitory effect of Smad7 AS on Smad7.
- 22 July 2020
- Published by MDPI AG in Biomedicines
- Vol. 8 (8) , 234
Open AccessA Novel Smad7 Genetic Variant Mapping on the Genomic Region Targeted by Mongersen Is Associated with Crohn’s Disease
Background: Down-regulation of Smad7 with a specific Smad7 antisense (AS) oligonucleotide-containing oral drug (Mongersen) was effective in pre-clinical studies and initial clinical trials in Crohn’s disease (CD) patients. A recent phase 3 trial was discontinued due to an apparent inefficacy of the drug, but factors contributing to the failure of this study remain unknown. Here, we analysed the frequency in CD of rs144204026 C/T single nucleotide polymorphism (SNP), which maps on the corresponding region targeted by the Smad7 AS contained in the Mongersen formulation and examined whether such a variant allele affects the ability of Smad7 AS to knockdown Smad7. Methods: rs144204026 SNP frequency was evaluated in two independent Italian cohorts of Crohn’s disease patients and normal controls. Genotyping was performed by allelic discrimination assay. Smad7 expression was evaluated in wild-type or heterozygous PBMCs treated with Smad7 AS. Results: No TT genotype was seen in CD patients and controls. Heterozygous genotype was more frequent in CD patients of both cohort 1 (11/235, 4.68%) and cohort 2 (8/122, 6.56%) as compared to controls (6/363, 1.65%; p = 0.029 and p = 0.01 respectively). Overall, a statistically significant association was observed between the T variant allele and CD patients’ susceptibility (p = 0.008; OR = 3.28, 95%CI: 1.3–8.3). Smad7 AS down-regulated Smad7 RNA independently of the presence of the variant allele. Conclusions: This is the first study to show an association between Smad7 rs144204026 SNP and CD patients. Data indicate that such a variant does not negatively influence the in vitro inhibitory effect of Smad7 AS on Smad7.
- Open Access
The Resolution of Intestinal Inflammation: The Peace-Keeper’s Perspective
The uncontrolled activation of the immune system toward antigens contained in the gut lumen in genetically predisposed subjects is believed to be the leading cause of inflammatory bowel disease (IBD). Two not mutually exclusive hypotheses can explain the pathogenic process leading to IBD. The first and mostly explored hypothesis states that the loss of tolerance toward gut microbiota antigens generates an aberrant inflammatory response that is perpetuated by continuous and unavoidable exposure to the triggering antigens. However, the discovery that the resolution of inflammation is not the mere consequence of clearing inflammatory triggers and diluting pro-inflammatory factors, but rather an active process in which molecular and cellular elements are involved, implies that a defect in the pro-resolving mechanisms might cause chronic inflammation in different immune-mediated diseases, including IBD. Here we review data on pro-resolving and counter-regulatory mechanisms involved in the resolution of inflammation, aiming to identify their possible involvement in the pathogenesis of IBD.
Open AccessThe Resolution of Intestinal Inflammation: The Peace-Keeper’s Perspective
The uncontrolled activation of the immune system toward antigens contained in the gut lumen in genetically predisposed subjects is believed to be the leading cause of inflammatory bowel disease (IBD). Two not mutually exclusive hypotheses can explain the pathogenic process leading to IBD. The first and mostly explored hypothesis states that the loss of tolerance toward gut microbiota antigens generates an aberrant inflammatory response that is perpetuated by continuous and unavoidable exposure to the triggering antigens. However, the discovery that the resolution of inflammation is not the mere consequence of clearing inflammatory triggers and diluting pro-inflammatory factors, but rather an active process in which molecular and cellular elements are involved, implies that a defect in the pro-resolving mechanisms might cause chronic inflammation in different immune-mediated diseases, including IBD. Here we review data on pro-resolving and counter-regulatory mechanisms involved in the resolution of inflammation, aiming to identify their possible involvement in the pathogenesis of IBD.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Mo1837 - Ultrasonographic Response to Anti-TNFs as Potential Treatment Target in Patients with Crohn's Disease
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Mo1837 - Ultrasonographic Response to Anti-TNFs as Potential Treatment Target in Patients with Crohn's Disease
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S642-S643
Treat to Target in Crohn’s Disease: Ultrasonographic Response is Associated with Better Outcomes
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S642-S643
Treat to Target in Crohn’s Disease: Ultrasonographic Response is Associated with Better Outcomes
- 1 August 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (8) , 852-858
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall colectomy-free survival and the identification of predictors of colectomy. The 3- and 12-month colectomy rates were 18.6% (95%CI 11.8%-26.9%) and 25.6% (95%CI 17.9%-34.7%) respectively. High CRP values and severe endoscopic lesions were associated with the risk of colectomy: Risk Ratio (RR)=2.15 (95%CI 1.05-4.36), and RR=5.13 (95%CI 1.55-16.96), respectively. In patients escaping early colectomy, the probability of a colectomy-free course at 12, 24, 36 and 60months was 91%, 85%, 81% and 73%, respectively. Endoscopic severity was the only predictor of long term colectomy (RR=7.0; 95%CI 1.09-44.7). Adverse events occurred in 16 patients (14%); there was one death (0.88%) due to pulmonary abscess. Infliximab is an effective and safe rescue therapy for severe corticosteroid-refractory ulcerative colitis. A three-dose induction regimen seems to be the treatment of choice for preventing early colectomy. Severe endoscopic lesions appear to be predictor of short- and long-term colectomy.
- 1 August 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (8) , 852-858
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall colectomy-free survival and the identification of predictors of colectomy. The 3- and 12-month colectomy rates were 18.6% (95%CI 11.8%-26.9%) and 25.6% (95%CI 17.9%-34.7%) respectively. High CRP values and severe endoscopic lesions were associated with the risk of colectomy: Risk Ratio (RR)=2.15 (95%CI 1.05-4.36), and RR=5.13 (95%CI 1.55-16.96), respectively. In patients escaping early colectomy, the probability of a colectomy-free course at 12, 24, 36 and 60months was 91%, 85%, 81% and 73%, respectively. Endoscopic severity was the only predictor of long term colectomy (RR=7.0; 95%CI 1.09-44.7). Adverse events occurred in 16 patients (14%); there was one death (0.88%) due to pulmonary abscess. Infliximab is an effective and safe rescue therapy for severe corticosteroid-refractory ulcerative colitis. A three-dose induction regimen seems to be the treatment of choice for preventing early colectomy. Severe endoscopic lesions appear to be predictor of short- and long-term colectomy.
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1199 Small Bowel Capsule Endoscopy for Assessing Early Postoperative Recurrence of Crohn's Disease: A Prospective Longitudinal Study
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1199 Small Bowel Capsule Endoscopy for Assessing Early Postoperative Recurrence of Crohn's Disease: A Prospective Longitudinal Study
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Tu1144 Could Infliximab Avoid Colectomy in Patients With Severe Ulcerative Colitis? A Multicentre Italian Experience
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Tu1144 Could Infliximab Avoid Colectomy in Patients With Severe Ulcerative Colitis? A Multicentre Italian Experience
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo1244 Psoriasis Phenotype in Inflammatory Bowel Disease
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo1244 Psoriasis Phenotype in Inflammatory Bowel Disease
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Tu1240 Colonic Phenotype of the Ileum in Crohn's Disease: Low Prevalence After Ileal Resection in a Prospective Longitudinal Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Tu1240 Colonic Phenotype of the Ileum in Crohn's Disease: Low Prevalence After Ileal Resection in a Prospective Longitudinal Study